Factors Predicting COVID-19 Vaccine Effectiveness and Longevity of Humoral Immune Responses

Overview

Journal Vaccines (Basel)

Date 2024 Nov 26

PMID 39591186

Authors

Engin Berber

Ted M Ross

Affiliations

Soon will be listed here.

Abstract

The COVID-19 pandemic, caused by SARS-CoV-2, prompted global efforts to develop vaccines to control the disease. Various vaccines, including mRNA (BNT162b2, mRNA-1273), adenoviral vector (ChAdOx1, Ad26.COV2.S), and inactivated virus platforms (BBIBP-CorV, CoronaVac), elicit high-titer, protective antibodies against the virus, but long-term antibody durability and effectiveness vary. The objective of this study is to elucidate the factors that influence vaccine effectiveness (VE) and the longevity of humoral immune responses to COVID-19 vaccines through a review of the relevant literature, including clinical and real-world studies. Here, we discuss the humoral immune response to different COVID-19 vaccines and identify factors influencing VE and antibody longevity. Despite initial robust immune responses, vaccine-induced immunity wanes over time, particularly with the emergence of variants, such as Delta and Omicron, that exhibit immune escape mechanisms. Additionally, the durability of the humoral immune responses elicited by different vaccine platforms, along with the identification of essential determinants of long-term protection-like pre-existing immunity, booster doses, hybrid immunity, and demographic factors-are critical for protecting against severe COVID-19. Booster vaccinations substantially restore neutralizing antibody levels, especially against immune-evasive variants, while individuals with hybrid immunity have a more durable and potent immune response. Importantly, comorbidities such as diabetes, cardiovascular disease, chronic kidney disease, and cancer significantly reduce the magnitude and longevity of vaccine-induced protection. Immunocompromised individuals, particularly those undergoing chemotherapy and those with hematologic malignancies, have diminished humoral responses and benefit disproportionately from booster vaccinations. Age and sex also influence immune responses, with older adults experiencing accelerated antibody decline and females generally exhibiting stronger humoral responses compared to males. Understanding the variables affecting immune protection is crucial to improving vaccine strategies and predicting VE and protection against COVID-19.

References

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J . Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18):1708-1720. PMC: 7092819. DOI: 10.1056/NEJMoa2002032. View

Altarawneh H, Chemaitelly H, Ayoub H, Tang P, Hasan M, Yassine H . Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. N Engl J Med. 2022; 387(1):21-34. PMC: 9258753. DOI: 10.1056/NEJMoa2203965. View

Lau J, Cheng S, Leung K, Lee C, Hachim A, Tsang L . Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population. Nat Med. 2023; 29(2):348-357. PMC: 9941049. DOI: 10.1038/s41591-023-02219-5. View

Renia L, Goh Y, Rouers A, Bert N, Chia W, Chavatte J . Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose. Nat Commun. 2022; 13(1):4615. PMC: 9358634. DOI: 10.1038/s41467-022-32312-1. View

Buoninfante A, Andeweg A, Baker A, Borad M, Crawford N, Dogne J . Understanding thrombosis with thrombocytopenia syndrome after COVID-19 vaccination. NPJ Vaccines. 2022; 7(1):141. PMC: 9643955. DOI: 10.1038/s41541-022-00569-8. View

Natarajan K, Prasad N, Dascomb K, Irving S, Yang D, Gaglani M . Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults -.... MMWR Morb Mortal Wkly Rep. 2022; 71(13):495-502. PMC: 8979598. DOI: 10.15585/mmwr.mm7113e2. View

Soheili M, Khateri S, Moradpour F, Mohammadzedeh P, Zareie M, Mahdavi Mortazavi S . The efficacy and effectiveness of COVID-19 vaccines around the world: a mini-review and meta-analysis. Ann Clin Microbiol Antimicrob. 2023; 22(1):42. PMC: 10198032. DOI: 10.1186/s12941-023-00594-y. View

Kertes J, Baruch Gez S, Saciuk Y, Supino-Rosin L, Shamir Stein N, Mizrahi-Reuveni M . Effectiveness of mRNA BNT162b2 Vaccine 6 Months after Vaccination among Patients in Large Health Maintenance Organization, Israel. Emerg Infect Dis. 2021; 28(2):338-346. PMC: 8798683. DOI: 10.3201/eid2802.211834. View

Tseng H, Ackerson B, Luo Y, Sy L, Talarico C, Tian Y . Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat Med. 2022; 28(5):1063-1071. PMC: 9117141. DOI: 10.1038/s41591-022-01753-y. View

10.

Sze S, Pan D, Nevill C, Gray L, Martin C, Nazareth J . Ethnicity and clinical outcomes in COVID-19: A systematic review and meta-analysis. EClinicalMedicine. 2020; 29:100630. PMC: 7658622. DOI: 10.1016/j.eclinm.2020.100630. View

11.

Solante R, Alvarez-Moreno C, Burhan E, Chariyalertsak S, Chiu N, Chuenkitmongkol S . Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic. Expert Rev Vaccines. 2022; 22(1):1-16. DOI: 10.1080/14760584.2023.2143347. View

12.

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

13.

Tartof S, Slezak J, Fischer H, Hong V, Ackerson B, Ranasinghe O . Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021; 398(10309):1407-1416. PMC: 8489881. DOI: 10.1016/S0140-6736(21)02183-8. View

14.

Anez G, Dunkle L, Gay C, Kotloff K, Adelglass J, Essink B . Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical Trial. JAMA Netw Open. 2023; 6(4):e239135. PMC: 10536880. DOI: 10.1001/jamanetworkopen.2023.9135. View

15.

Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B . Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021; 384(23):2187-2201. PMC: 8220996. DOI: 10.1056/NEJMoa2101544. View

16.

Fink A, Engle K, Ursin R, Tang W, Klein S . Biological sex affects vaccine efficacy and protection against influenza in mice. Proc Natl Acad Sci U S A. 2018; 115(49):12477-12482. PMC: 6298067. DOI: 10.1073/pnas.1805268115. View

17.

Saban M, Myers V, Ben-Shetrit S, Wilf-Miron R . Socioeconomic gradient in COVID-19 vaccination: evidence from Israel. Int J Equity Health. 2021; 20(1):242. PMC: 8574141. DOI: 10.1186/s12939-021-01566-4. View

18.

Bauer G . The potential significance of high avidity immunoglobulin G (IgG) for protective immunity towards SARS-CoV-2. Int J Infect Dis. 2021; 106:61-64. PMC: 7944804. DOI: 10.1016/j.ijid.2021.01.061. View

19.

Follmann D, Mateja A, Fay M, Magaret C, Huang Y, Fong Y . Durability of Protection Against COVID-19 Through the Delta Surge for the NVX-CoV2373 Vaccine. Clin Infect Dis. 2024; 79(1):78-85. PMC: 11259228. DOI: 10.1093/cid/ciae081. View

20.

Oosting S, van der Veldt A, GeurtsvanKessel C, Fehrmann R, van Binnendijk R, Dingemans A . mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. Lancet Oncol. 2021; 22(12):1681-1691. PMC: 8577843. DOI: 10.1016/S1470-2045(21)00574-X. View